Abstract Library

#3843 VIPoma presenting as chronic diarrhea in a 30-year-old Filipino female

Introduction: Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. They can secrete a variety of peptide hormones including insulin, gastrin, glucagon, and vasoactive intestinal peptide. Secretory tumors such as vasoactive intestinal polypeptides are rare neuroendocrine pancreatic neoplasms characterized by watery diarrhea, hypokalemia, and hypochlorhydria.

Conference:

Presenting Author: Edejer P

Authors: Edejer P, Mendoza R, Pascasio C, Lin T, Cornelio G,

Keywords: Pancreatic NET, Octreotide, DOTATATE, diarrhea,

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,

#3467 Correlation study between 68Ga-DOTATOC PET/CT metrics and 177Lu-DOTATATE dosimetry for non-pancreatic neuroendocrine tumors

Introduction: 177Lu-DOTATATE therapy is validated for the management of well-differentiated metastatic, somatostatin receptor expressing non-pancreatic neuroendocrine tumors (npNETs). The evaluation of the tissue absorbed dose (D) could allow to assess the risk-benefit ratio of PRRT. Unfortunately, due its complexity, dosimetry study is hardly performed in routine.

Conference:

Presenting Author:

Authors: Texier J, Jocmek M, Dierickx L, Vallot D, Brillouet S,

Keywords: 68Ga-DOTATOC PET/CT, non-pancreatic neuroendocrine tumor, 177Lu-DOTATATE, dosimetry,

#3270 Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors

Introduction: Lu-177 DOTATATE® is a proficient systemic irradiation with heterogeneous individual consequences due to tumor burden, uptake and elimination. Current dosimetry protocols seem not accurate enough to predict efficacy or toxicity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Courbon F

Authors: Brahmi S, Vallot D, Vija L, Dierickx L, Courbon F,

Keywords: midgut NET, Ga DOTA PET CT, LuPRRT, PET metrics, SUV, tumor absorbed dose,

#2281 A Novel Classification of Pancreatic Neuroendocrine Tumors (pNETs) Guided by Genomics

Introduction: NET outcomes differ by primary site. Yet pNETs are classified using a generic GI grading system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lawrence B

Authors: Lawrence B, Blenkiron C, Parker K, Yeong M, Kramer N,

Keywords: pancreatic NET, genomics,